908 Devices Inc. (NASDAQ:MASS – Get Free Report) Director Christopher Brown sold 30,000 shares of the stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $11.89, for a total transaction of $356,700.00. Following the sale, the director owned 745,559 shares in the company, valued at approximately $8,864,696.51. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
908 Devices Stock Up 4.3%
MASS stock traded up $0.50 during midday trading on Friday, reaching $12.05. The company had a trading volume of 323,080 shares, compared to its average volume of 336,948. The stock has a 50 day moving average price of $10.44 and a 200 day moving average price of $8.60. 908 Devices Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $13.35. The firm has a market capitalization of $498.07 million, a PE ratio of -12.68 and a beta of 0.63.
908 Devices (NASDAQ:MASS – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The business had revenue of $16.07 million for the quarter, compared to analysts’ expectations of $15.37 million. 908 Devices had a negative return on equity of 12.54% and a negative net margin of 56.96%. Research analysts predict that 908 Devices Inc. will post -0.59 EPS for the current year.
Institutional Trading of 908 Devices
Analysts Set New Price Targets
Several equities analysts have recently commented on the stock. Roth Capital upped their price target on shares of 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a research note on Friday, August 7th. Canaccord Genuity Group began coverage on shares of 908 Devices in a research report on Thursday, September 10th. They issued a “buy” rating and a $13.50 target price for the company. Stifel Nicolaus raised their price target on shares of 908 Devices from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen cut 908 Devices from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.83.
Check Out Our Latest Analysis on 908 Devices
About 908 Devices
908 Devices Inc is a Boston-based technology company that develops and manufactures handheld and portable chemical detection and analysis instruments. Its products are designed to help users identify and characterize chemical substances in the field, at industrial sites and in laboratory settings without requiring samples to be transported to a centralized facility.
The company’s product portfolio includes the MX908 and related devices for detecting and identifying trace chemicals, explosives, narcotics and other substances; the Xplora platform for field and process analysis; and ZipChip technologies used for rapid, high-resolution separations in life sciences and biopharmaceutical research.
See Also
- Five stocks we like better than 908 Devices
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.
